FCSC - Fibrocell Science, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9941
+0.0141 (+0.71%)
As of 1:44PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.9800
Open2.0300
Bid1.9600 x 900
Ask2.0200 x 41800
Day's Range1.8600 - 2.0725
52 Week Range1.7500 - 14.5500
Volume73,683
Avg. Volume195,740
Market Cap18.575M
Beta (3Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire23 days ago

    Fibrocell to Present at Upcoming Industry and Investor Conferences

    EXTON, Pa., Sept. 26, 2018 -- Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and.

  • GlobeNewswire24 days ago

    Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) has awarded a $1.4 million clinical trial research grant for Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating, rare skin blistering disease with high mortality. “We are delighted with the FDA’s recognition to support the ongoing progress of our clinical trials of FCX-007,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • GlobeNewswirelast month

    Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma—a chronic, debilitating genetic skin disorder with no FDA approved therapies. “Fast Track designation represents an important milestone in advancing clinical development of FCX-013,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • GlobeNewswire2 months ago

    Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “During the second quarter of 2018, we attained important milestones that continue to advance the development of our gene therapy candidates for rare and devastating conditions affecting the skin and connective tissue,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • ACCESSWIRE2 months ago

    Fibrocell Science, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...

  • GlobeNewswire3 months ago

    Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the second quarter ended June 30, 2018 and recent operational highlights on Thursday, August 9, 2018 before the open of the U.S. financial markets.  Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks. Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue.  Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa.

  • What's in Store for Intrexon (XON) This Earnings Season?
    Zacks3 months ago

    What's in Store for Intrexon (XON) This Earnings Season?

    Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.

  • ACCESSWIRE3 months ago

    Free Technical Research on Evolus and Three More Generic Drugs Equities

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on EOLS sign up now at www.wallstequities.com/registration. On Tuesday, July 24, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.79% and 0.48% higher, respectively at the closing bell, while the NASDAQ Composite stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drugs - Generic equities this morning: Evolus Inc. (EOLS), Fibrocell Science Inc. (NASDAQ: FCSC), Flexion Therapeutics, Inc. (NASDAQ: FLXN), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA).

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...

  • Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?
    Zacks5 months ago

    Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?

    Fibrocell Science, Inc. (FCSC) has been struggling lately, but the selling pressure may be coming to an end soon

  • ACCESSWIRE5 months ago

    Blog Exposure - Fibrocell Presented Update on Interim Results and Progress of its Phase-1/2 Clinical Trial of FCX-007 at International Investigative Dermatology Meeting

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Fibrocell Science, Inc. (NASDAQ: FCSC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FCSC as the Company's latest news hit the wire. On May 21, 2018, the Company presented an update on the interim results and progress of its Phase-1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) at the 7th International Investigative Dermatology (IID) meeting held on May 19, 2018. Active-Investors.com is currently working on the research report for OptiNose, Inc. (NASDAQ: OPTN), which also belongs to the Healthcare sector as the Company Fibrocell Science.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 16) Abaxis Inc (NASDAQ: ABAX ) (announced a deal to be bought ...

  • What's in Store for Intrexon (XON) This Earnings Season?
    Zacks6 months ago

    What's in Store for Intrexon (XON) This Earnings Season?

    Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.